Introduction: Urinary tract infections (UTI) in patients with neurogenic lower urinary tract dysfunction (NLUTD) are defined as complicated UTI requiring antibiotic treatment. As the emergence of multiresistant strains is a serious problem, we assessed the feasibility of nonantibiotic treatment of UTI in patients with NLUTD. Materials and Methods: In a prospective study evaluating the usefulness of UTI prophylaxis, participants could opt for either antibiotic or nonantibiotic treatment of breakthrough UTI. If either symptoms persisted for 48 h or a febrile UTI occurred, antibiotic treatment based on microbiological testing was mandatory. Treatment efficacy, complications, and emergency hospital visits were assessed. Results: Within the observation period (1 year), the 25 participants developed 206 UTI. Seven febrile UTI required immediate antibiotic treatment. Of the remaining 199 UTI, patients chose antibiotic treatment in 104 events, whereas in 95 events, patients chose either nonantibiotic interventions (n = 80) or no treatment at all (n = 15). Success rates were 78.8% for antibiotic treatment, 67.5% with nonantibiotic treatments, and 26% without therapy. Of the 7 patients with initially febrile UTI, 2 required hospitalization due to septicemia. Conclusions: Nonantibiotic treatment seems to be a feasible alternative to antibiotic therapy in patients with complicated UTI as well, provided there is no fever.

Keywords:
Neurogenic lower urinary tract dysfunction, Urinary tract infections, Multiresistant bacteria, Antibiotics
1.
Vigil HR, Hickling DR: Urinary tract infection in the neurogenic bladder. Transl Androl Urol 2016; 5: 72–87.
2.
Esclarin De Ruz A, Garcia Leoni E, Herruzo Cabrera R: Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol 2000; 164: 1285–1289.
3.
Biering-Sorensen F, Nielans HM, Dørflinger T, Sørensen B: Urological situation five years after spinal cord injury. Scand J Urol Nephrol 1999; 33: 157–161.
4.
Everaert K, Lumen N, Kerckhaert W, ­Willaert P, van Driel M: Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg 2009; 64: 335–340.
5.
Pickard R, Bartoletti R, Bjerklund-Johansen TE, Bonkat G, Bruyère F, Çek M, Grabe M, Tenke P, Wagenlehner F, Wullt B, Cai T, Köves B, Pilatz A, Pradere B, Veeratterapillay R: EAU Guidelines on Urological Infections. https://uroweb.org/guideline/urological-infections/ (accessed November 20, 2017).
6.
Lindbäck H, Lindbäck J, Melhus Å: Inadequate adherence to Swedish guidelines for uncomplicated lower urinary tract infections among adults in general practice. APMIS 2017; 125: 816–821.
7.
Goetz LL, Cardenas DD, Kennelly M, Bonne Lee BS, Linsenmeyer T, Moser C, Pannek J, Wyndaele JJ, Biering-Sorensen F: International spinal cord injury urinary tract infection basic data set. Spinal Cord 2013; 51: 700–704.
8.
Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Schneider M, 't Hoen L, Blok B: Summary of European association of urology (EAU) guidelines on neuro-urology. Eur Urol 2016; 69: 324–333.
9.
Waisse S: The science of high dilutions in historical context. Homeopathy 2012; 101: 129–137.
10.
Wagenlehner FM, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensieck W, Watermann D, Naber KG: [National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients]. Urologe A 2011; 50: 153–169.
11.
Böthig R, Domurath B, Kaufmann A, Bremer J, Vance W, Kurze I: [Neuro-urological diagnosis and therapy of lower urinary tract dysfunction in patients with spinal cord injury : S2k Guideline of the German-Speaking Medical Society of Paraplegia (DMGP), AWMF register no. 179/001]. Urologe A 2017; 56: 785–792.
12.
Wagenlehner FM, Naber KG: Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles. Expert Rev Anti Infect Ther 2004; 2: 923–931.
13.
Krebs J, Wöllner J, Pannek J: Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord 2016; 54: 682–686.
14.
Brommer B, Engel O, Kopp MA, Watzlawick R, Müller S, Prüss H, Chen Y, DeVivo MJ, Finkenstaedt FW, Dirnagl U, Liebscher T, Meisel A, Schwab JM: Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level. Brain 2016; 139: 692–707.
15.
Pavlicek D, Krebs J, Capossela S, Bertolo A, Engelhardt B, Pannek J, Stoyanov J: Immunosenescence in persons with spinal cord injury in relation to urinary tract infections -a cross-sectional study. Immun Ageing 2017; 14: 22.
16.
Ibrahim NH, Maruan K, Mohd Khairy HA, Hong YH, Dali AF, Neoh CF: Economic evaluations on antimicrobial stewardship programme: a systematic review. J Pharm Pharm Sci 2017; 20: 397–406.
17.
Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M; MR2 study group: Impact of the medical specialty on knowledge regarding multidrug-resistant organisms and strategies toward antimicrobial stewardship. Int Urol Nephrol 2017; 49: 1311–1318.
18.
Pannek J: Treatment of urinary tract infection in persons with spinal cord injury: guidelines, evidence, and clinical practice. A questionnaire-based survey and review of the literature. J Spinal Cord Med 2011; 34: 11–15.
19.
Jonas WB, Kaptchuk TJ, Linde K: A critical overview of homeopathy. Ann Intern Med 2003; 138: 393–399.
20.
Bellavite P, Marzotto M, Olioso D, Moratti E, Conforti A: High-dilution effects revisited. 2. Pharmacodynamic mechanisms. Homeopathy 2014; 103: 22–43
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.